Hyphens Pharma International Limited

1J5

SG1EE4000006

Pharmaceuticals

Delayed Singapore S.E. Other stock markets 09:55:04 2024-05-07 pm EDT			5-day change	1st Jan Change
0.265 ^SGD	-3.64%		-3.64%	-7.02%

Apr. 25	Hyphens Pharma International Limited Approves a Final Tax Exempt (One-Tier) Dividend for the Financial Year Ended 31 December 2023	CI
Apr. 09	Hyphens Pharma’s Attributable Profit Narrows in 2023	MT

Hyphens Pharma International Limited Reports Earnings Results for the First Quarter Ended March 31, 2021

May 12, 2021 at 07:04 am EDT

Hyphens Pharma International Limited announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was SGD 33.790 million compared to SGD 31.441 million a year ago. Net income was SGD 2.136 million compared to SGD 2.124 million a year ago.

Latest news about Hyphens Pharma International Limited

Hyphens Pharma International Limited Approves a Final Tax Exempt (One-Tier) Dividend for the Financial Year Ended 31 December 2023	Apr. 25	CI
Hyphens Pharma’s Attributable Profit Narrows in 2023	Apr. 09	MT
Hyphens Pharma International Limited Proposes Final Tax Exempt (One-Tier) Dividend	Apr. 08	CI
Hyphens Pharma Buys Back Shares	Apr. 02	MT
CGS-CIMB Adjusts Hyphens Pharma’s Price Target to SG$0.35 From SG$0.32, Keeps at Add	Mar. 15	MT
Hyphens Pharma Obtains License to MC2's Psoriasis Cream	Mar. 13	MT
Hyphens Pharma International Limited Signs Exclusive Distribution Agreement with Cooper Pharma, S.A	Feb. 29	CI
Hyphens Pharma International Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Hyphens Pharma Strikes Distribution Deal With 7-Eleven Singapore	Feb. 13	MT
Hyphens Pharma Partners 7-Eleven to Offer Ocean Health Supplements in Singapore	Feb. 06	CI
Hyphens Pharma International Grants Nearly 6 Million Shares Under Performance Share Plan	Dec. 11	MT
CGS-CIMB Adjusts Hyphens Pharma’s Price Target to SG$0.32 From SG$0.34, Keeps at Add	Nov. 28	MT
Hyphens Pharma International Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Hyphens Pharma Unit Completes Purchase of First Tranche of Remaining Ardence Pharma Stake	Nov. 08	MT
Hyphens Pharma to Acquire Remaining 58% Stake in Ardence Pharma	23-10-18	MT
Hyphens Pharma Unit to Distribute Daewoong Pharmaceutical's Nabota Botox in Malaysia	23-08-30	MT
Hyphens Pharma International Limited Announces Special Interim Tax Exempt (One-Tier) Dividend for the Financial Year Ending 31 December 2023, Paid on 31 August 2023	23-08-10	CI
Hyphens Pharma International Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-10	CI
Hyphens Pharma Names CFO	23-06-05	MT
Hyphens Pharma International Limited Appoints Zhang Yufan as Chief Financial Officer	23-06-05	CI
Singapore Shares Return to Green; Hyphens Pharma Rises 5% on Deal to Develop Sedation Drug in Singapore	23-05-18	MT
Hyphens Pharma to Develop, Commercialize Hana Pharm's Sedation Drug in Singapore	23-05-18	MT
Singapore Stocks End Week in Red; Hyphens Pharma Shares Plummet 12% as Net Profit Dives 57% in Q1	23-05-12	MT
Hyphens Pharma's Net Profit Dives 57% in Q1; Shares Fall 14%	23-05-12	MT
Hyphens Pharma International Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI

Chart Hyphens Pharma International Limited

Duration

Period

Chart Hyphens Pharma International Limited

More charts

Company Profile

Hyphens Pharma International Limited is a Singapore-based specialty pharmaceutical and consumer healthcare company. The Company's principal activities are those of an investment holding company and provision of management services. The Company's segments include Specialty pharma principals, Proprietary brands, and Medical hypermart and digital. The Specialty pharma principals segment is engaged in the business of marketing and selling a range of specialty pharmaceutical products with exclusivity in the relevant ASEAN countries. The Proprietary brands segment is engaged in the business of developing, marketing and selling its own proprietary range of dermatological products and health supplement products. The Medical hypermart and digital segment is a wholesaler of pharmaceuticals and medical supplies in Singapore, which the Company and its subsidiaries position themselves as a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Hyphens Pharma International Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.275 SGD

Average target price

0.35 SGD

Spread / Average Target

+27.27%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
HYPHENS PHARMA INTERNATIONAL LIMITED	-7.02%	62.84M
MCKESSON CORPORATION	+17.88%	70.09B
CARDINAL HEALTH, INC.	-1.07%	24.01B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+8.01%	8.32B
HUADONG MEDICINE CO., LTD	-18.28%	8.23B
SINOPHARM GROUP CO. LTD.	+1.96%	8.08B
H. LUNDBECK A/S	+4.40%	4.68B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+16.55%	4.41B
EBOS GROUP LIMITED	-0.70%	4.12B
GALENICA AG	-2.20%	3.88B

Pharmaceuticals Wholesale